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Objectives: The relationship between cancer and thrombosis was ﬁrst recognized by the French internist
Armand Trousseau in 1865. Trousseau's syndrome is a spectrum of symptoms that result from recurrent
thromboembolism associated with cancer or malignancy-related hypercoagulability. In this study, we
investigated whether demographics, clinical features, or laboratory ﬁndings were able to predict
recurrent stroke episodes in patients with Trousseau's syndrome.
Methods: In total, 178 adult patients were enrolled in this retrospective cross-sectional study. All patients
had been admitted to the emergency room of our hospital between January 2011 and September 2014
and were diagnosed with acute ischemic stroke. Patients were divided into two groups: patients with
malignancy (Trousseau's syndrome), and patients without malignancy.
Results: There were several signiﬁcant differences between the laboratory results of the two patient
groups. For patients with Trousseau's, the hemoglobin levels for those with one stroke was 12.29 ± 1.81,
while those in patients who had experienced more than one stroke was 10.94 ± 2.14 (p ¼ 0.004).
Conclusions: Trousseau's syndrome is a cancer-associated coagulopathy associated with high morbidity
and mortality rates. In this study, anemia was associated with increased stroke recurrence in patients
with malignancy (Trousseau's syndrome).
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Among the neurological diseases, cerebrovascular diseases are
the most common in developed countries. Stroke is the most
common cause of death in these countries, and neoplastic diseases
(cancer and hematologic tumors) are the second most common
cause. However, stroke is a rare complication of cancer therapy, and
does not occur as often as metastasis or neurotoxicity.1,2y Medicine, Haseki Training
Istanbul, Turkey. Tel.: þ90
ncy Medicine Association of
e Association of Turkey. Production
ons.org/licenses/by-nc-nd/4.0/).A retrospective autopsy study of a large cohort of cancer pa-
tients performed by Graus et al showed that 15% of cancer patients
have evidence of cerebrovascular disease, and about half of these
patients have clinical symptoms of stroke.3
In this study, we retrospectively analyzed the demographic,
clinical, and laboratory data of cancer and cancer-free patients that
presentedwith acute ischemic stroke in the emergency department.
2. Materials and methods
2.1. Study population
A retrospective cross-sectional study including 178 adult pa-
tients was carried out after taking approval from institutional ethics
committee. We retrospectively investigated patients who wereand hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
Table 1
Demographic and clinical characteristics of ischemic stroke patients with malig-
nancy (group 1) versus those with no malignancy (group 2).
Group 1 (n ¼ 91) Group 2 (n ¼ 87) pa
Age (years) 65.18 ± 11.98 62.80 ± 1 2.23 0.193
Gender (Female/Male) 31/60 31/56 0.828
Smoking 64 52
Drinking 44 21
Previous stroke history 24 15
Hypertension 50 59
Diabetes mellitus 27 36
CAD 40 32
Hyperlipidemia 18 4
COPD 11 7
CHF 9 1
Liver Cirrhosis 5 e
CRF 3 1
Group 1, the ischemic stroke patients with malignancy (trousseau group); Group 2,
the ischemic stroke patients with no malignancy; CAD, coronary arterial disease;
COPD, chronical obstructive pulmonary disease; CHF, chronical heart failure; CRF,
chronical renal failure.
a Student's t-test.
Table 2
Laboratory values of ischemic stroke patients with malignancy (group 1) and those
patients with no malignancy (group 2) at the time of presentation.
Parameters Group 1 (n ¼ 91) Group 2 (n ¼ 87) pa
BUN (mg/dl) 25.19 ± 14.29 18.05 ± 7.01 <0.001
Cre (mg/dl) 1.02 ± 0.47 0.90 ± 0.30 0.034
AST (U/L) (13e584) (9e88) 0.004
ALT (U/L) (6e236) (6e71) 0.001
Hematocrit (%) 36.24 ± 5.84 41.20 ± 5.20 <0.001
D.dimer (ug FEU/ml) (0.10e11.55) (0.10e8.70) <0.001
CRP (mg/dl) (0.10e27.60) (0.10e14.40) <0.001
Hemoglobin (g/dl) 11.93 ± 1.98 13.61 ± 1.92 <0.001
Platelets (103mL) 262.58 ± 107.45 233.25 ± 66.35 <0.001
Group 1, the ischemic stroke patients with malignancy (trousseau group); Group 2,
the ischemic stroke patients with no malignancy. BUN, blood urine nitrogene; Cre,
creatinine; AST, aspartate transaminase; ALT, alanine transaminase; CRP, c-reactive
protein.
a Student's t-test.
Fig. 1. Comparison of hemoglobin levels (median (interquartile range)) between
Trousseau's group patients who had one stroke (group 1A) and those patients who had
more than one stroke (group 1B) at the time of presentation.
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between January 1st, 2011 and July 15th, 2014. Medical history and
physical examination data were obtained from all patients who
were diagnosed with acute ischemic stroke. Acute ischemic stroke
diagnoses were conﬁrmed by further imaging tests of the brain,
including computed tomography (CT) and diffusion-weighted
magnetic resonance imaging (DW-MRI).
The ischemic stroke patients were divided into two groups:
group 1; patients with active cancer (Trousseau's) and group 2;
those without. Active cancer was deﬁned as a conﬁrmed malig-
nancy, which was either treated or untreated in the six months
before stroke.4 Demographic characteristics and clinical data were
collected and evaluated. These two groups were then divided into
subgroups: those who had had one stroke (groups 1A and 2A) and
those who had more than one (groups 1B and 2B). Patients who
were diagnosed with transient ischemia or who had no evidence of
either acute or chronic infarction after neuroimaging were
excluded from the study. Patients with primary brain cancer and
patients who had intracranial metastases were also excluded since
these patients were thought to have different underlying stroke
mechanisms.
2.2. Statistical analysis
All data was analyzed using SPSS software (version 15.0; SPSS
Inc., Chicago, IL). The chi-square test was used to compare stroke
risk factors and subtypes between cancer patients who had expe-
rienced one ischemic stroke and those who had experienced more
than one. A student's t-test was used to compare biomarkers be-
tween the two groups. P value of <0.05 was considered statistically
signiﬁcant.
3. Results
Among the 200 adult patients referred to the EDwith stroke, we
identiﬁed 178 patients who were diagnosed as acute ischemic
stroke. Nine patients with transient ischemia, eight patients with
primary brain cancer and ﬁve patients who had intracranial me-
tastases were excluded from the study. The active cancer group
(group 1) included 91 patients (60 male, 31 female), and the stroke
without cancer group (group 2) included 87 (56 male, 31 female).
The mean age was 65.18 ± 11.98 among those with cancer and
62.80 ± 12.23 among those without; this difference was not sig-
niﬁcant (p ¼ 0.193). Among the patients with active cancer, 24 had
previously experienced a stroke whereas in the group without
cancer, 15 had previously experienced a stroke. The demographic
and clinical characteristics are shown in Table 1.
Laboratory tests, including blood urine nitrogen, creatinine,
aspartate transaminase, alanine transaminase, hematocrit, D-
dimer, C-reactive protein, hemoglobin, and platelet counts, were
obtained for all patients, and signiﬁcant differences were found
between groups for all parameters (p < 0.05). The patients' labo-
ratory values are shown in Table 2.
Patients with active cancer were divided into two subgroups
based on the number of strokes experienced after malignancy
diagnosis: only one stroke (n ¼ 67; group 1A) or more than one
(n ¼ 24; group 1B) were. Hemoglobin and hematocrit levels were
signiﬁcantly greater among patients who had only one stroke:
hemoglobin, 12.29 ± 1.81 vs. 10.94 ± 2.00 (p ¼ 0.004, Fig. 1) and
hematocrit, 37.15 ± 5.34 vs. 33.70 ± 6.51 (p ¼ 0.012). Laboratory
values for the two subgroups are shown in Table 3.
Among patients without cancer, laboratory values did not differ
between thosewho had experienced only one stroke (n¼ 72; group
2A) and those who had multiple strokes (n ¼ 15; group 2B)
(Table 4).
Table 4
Laboratory values of cancer-free patients who suffered their ﬁrst stroke (group 2A)
and those patients who suffered recurrent stroke (group 2B) at the time of
presentation.
Parameters Group 2A (n ¼ 72) Group 2B (n ¼ 15) pa
BUN (mg/dl) 17.85 ± 6.84 19.06 ± 7.97 0.545
Cre (mg/dl) 0.90 ± 0.32 0.87 ± 0.15 0.706
AST (U/L) 23.10 ± 10.74 23.20 ± 6.04 0.972
ALT (U/L) 21.79 ± 11.75 22.40 ± 9.37 0.851
Hematocrit (%) 41.69 ± 5.16 38.89 ± 4.90 0.058
D.dimer (ug FEU/ml) (0.10e11.55) (0.10e14.40) 0.649
CRP (mg/dl) (0.30e1.60) (0.20e3.90) 0.874
Hemoglobin (g/dl) 13.77 ± 1.87 12.83 ± 2.00 0.084
Platelets (103 mL) 230.05 ± 64.38 249.73 ± 75.41 0.299
Group 2A, consisted of ischemic stroke patients who had one stroke; Group 2B,
consisted of ischemic stroke patients who had more than one stroke. BUN, blood
urine nitrogene; Cre, creatinine; AST, aspartate transaminase; ALT, alanine trans-
aminase; CRP, c-reactive protein.
a Chi-square test.
Table 5
Types of cancer in ischemic stroke patients with malignancy (Traussea's group).
Cancer type Patient numbers and percentages (n ¼ 91) (%)
Prostate cancer 21 (23.08%)
Lung cancer 14 (15.38%)
Skin cancer 9 (9.89%)
Gastric cancer 11 (12.09%)
Colon cancer 6 (6.59%)
Lymphoma 4 (4.39%)
Hepatocellular carcinoma 5 (5.49%)
Breast cancer 5 (5.49%)
Renal cancer 5 (5.49%)
Cervix cancer 3 (3.31%)
Pancreatic cancer 3 (3.31%)
Others 5 (5.49%)
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prostate cancer, 14 with lung cancer, 11 with gastric cancer, and
nine with skin cancer (Table 5).
4. Discussion
Kim et al5 reported that d-dimer, pro-BNP, and ﬁbrinogen levels
were higher in ischemic stroke patients with cancer compared to
those without. Consistent with the literature,5 d-dimer levels in the
present study were signiﬁcantly higher in cancer patients. These
results imply a relationship between cancer and inﬂammation,
thrombus formation, and coagulopathy, which could explain the
increased frequency of ischemic stroke in cancer patients compared
with non-cancer patients.5
Kim et al found that among stroke patients with cancer, 33
(21.2%) had gastric cancer, 25 (16%) had lung cancer, 22 (14.1%) had
colon cancer, 20 (12.8%)hadhepatobiliarycancer, and84 (53.8%)had
metastases.4 In the present study, 21 patients were diagnosed with
prostate cancer (23.08%), 14 with lung cancer (15.38%), 11 with
gastric cancer (12.09%), and 9 with skin cancer (9.89%).
C-reactive protein is an acute peptide related to inﬂammation and the
progression of hemangioendothelioma, and increases during systemic
inﬂammation and atherosclerotic disease.6 Previous studies showed that
leukocyte count and levels of ﬁbrinogen and C-reactive protein (CRP) may
serve as markers of inﬂammatory activity. Inﬂammatory activity increases
the risk for vascular events andworsens prognosis after a stroke.7e15 In the
present study, CRP levels were 0.10e27.60 Unit (U) acute ischemic stroke
patients with malignancy (Trousseau's syndrome), and 0.10e14.40 U in
stroke patients with no malignancy, a statistically signiﬁcant difference
(p< 0.001).
Among the hematopoietic growth factors, erythropoiesis-stimulating
agents (ESAs) are frequently used in oncology due to their ability to cor-
rect chemotherapy-induced bone marrow suppression and anemia; how-
ever, administration of ESAs to patients with cancer is associated with
increasedrisks forvenous thromboembolism,highermortality,16,17 andeven
tumor progression.18 In the present study, hemoglobin levels were
11.93±1.98 instrokepatientswithmalignancy (Trousseau's syndrome), and
13.61 ± 1.92 in stroke patients without, also a signiﬁcant difference
(p<0.001). Thus, inpatientswithmalignancies, stroke is stronglyassociated
with anemia. In our study, among the subgroups, hemoglobin levels were
12.29 ± 1.81 for the patients who had experienced only one stroke, and
10.94 ± 2.14 for the patients who had experienced multiple strokes, and
again, these values were signiﬁcantly different (p ¼ 0.004). This data sug-
gests that there is a strong correlation between increasednumberof strokes
and degree of anemia.
Smoking is a common risk factor in both ischemic stroke and
cancer, and is also the cause of most ischemic strokes in cancerTable 3
Laboratory values of trousseau group patients who had one stroke (group 1A) and
those patients who hadmore than one stroke (group 1B) at the time of presentation.
Parameters Group 1A (n ¼ 67) Group 1B (n ¼ 24) pa
BUN (mg/dl) 25.43 ± 14.46 24.50 ± 14.08 0.785
Cre (mg/dl) 1.04 ± 0.49 0.98 ± 0.41 0.564
AST (U/L) (14e584) (13e78) 0.346
ALT (U/L) (7e236) (6e145) 0.732
Hematocrit (%) 37.15 ± 5.34 33.70 ± 6.51 0.012
D-dimer (ug FEU/ml) (0.10e8.10) (0.30e8.70) 0.445
CRP (mg/dl) (0.10e27.60) (0.20e26.80) 0.534
Hemoglobin (g/dl) 12.29 ± 1.81 10.94 ± 2.14 0.004
Platelets (103 mL) 255.92 ± 96.70 281.17 ± 133.66 0.326
Group 1A, consisted of trousseau group patients who had one stroke; Group 2B,
consisted of trousseau group patients who had more than one stroke. BUN, blood
urine nitrogene; Cre, creatinine; AST, aspartate transaminase; ALT, alanine trans-
aminase; CRP, c-reactive protein.
a Chi-square test.patients.2,11 Most reports have found that hypertension and
smoking are the most common causes of ischemic stroke in cancer
patients,11e15 and these results correlate well with our ﬁndings. In
our study, there was a higher incidence of both smoking and hy-
pertension among Trousseau's patients (n ¼ 64, 70.32%; n ¼ 50,
54.94%, respectively).
5. Limitations
One limitation of this presented cross-sectional, retrospective
analysis is that the sample is small and the other is that the study
design limits the degree of change in anemiawhichmay have led to
recurrence of ischemic stroke in patients with Trousseau's syn-
drome. This issue in limitation should be considered in case-control
studies with larger sample size.
6. Conclusions
In this preliminary study, we observed that repeated episodes of
stroke in patients with Trousseau's syndrome seem to occur more
frequently in the presence of anemia. Therefore, we suggest that
restoration of hemoglobin levels may help prevent recurrent stroke
in patients with Trousseau's syndrome.
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